The objective of the Biometry Core is to provide data management and computing support for all projects, and to collaborate with project investigators in the development and application of statistical methods for design and analysis. This goal is achieved through the following specific aims: 1. To provide statistical design and review of laboratory and clinical studies including feasibility assessment and sample size estimation. 2. To develop procedures for data collection and to maintain computer databases for information storage and retrieval. 3. To provide statistical collaboration in the execution and analysis of all program project studies. 4. To interpret the statistical and clinical literature relevant to all projects, and to develop new study design and data analysis procedures to meet program project objectives. Biometry support is required in all phases of program project studies. During study design the core will address statistical power and sample size issues, and will work with study investigators to establish data management procedures. Upon study completion, the core performs statistical analyses in collaboration with study investigators. Core personnel will also prepare and assist in the preparation of manuscripts for publication. The Biometry Core continues to be used by all program project investigators in both laboratory and clinical settings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA017094-29
Application #
7678548
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
29
Fiscal Year
2008
Total Cost
$58,356
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35
Barrett, Harrison H; Alberts, David S; Woolfenden, James M et al. (2016) Therapy operating characteristic curves: tools for precision chemotherapy. J Med Imaging (Bellingham) 3:023502
Chang, Hae Ryung; Nam, Seungyoon; Kook, Myeong-Cherl et al. (2016) HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 65:19-32
Malm, Scott W; Hanke, Neale T; Gill, Alexander et al. (2015) The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J Exp Clin Cancer Res 34:31
Samulitis, Betty K; Pond, Kelvin W; Pond, Erika et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16:43-51
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Dragovich, T; Laheru, D; Dayyani, F et al. (2014) Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol 74:379-87
Exley, Mark A; Hand, Laura; O'Shea, Donal et al. (2014) Interplay between the immune system and adipose tissue in obesity. J Endocrinol 223:R41-8
Zhang, Xiaomeng; Pagel, Mark D; Baker, Amanda F et al. (2014) Reproducibility of magnetic resonance perfusion imaging. PLoS One 9:e89797
Jagadish, Bhumasamudram; Ozumerzifon, Tarik J; Roberts, Sue A et al. (2014) IMPROVED SYNTHESIS OF 10-(2-ALKYLAMINO-2-OXOETHYL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID DERIVATIVES BEARING ACID-SENSITIVE LINKERS. Synth Commun 44:

Showing the most recent 10 out of 314 publications